4 Balzan 2009 prize winners announce... (nces ) read the motivation for the assig...)

4 Balzan 2009 prize winners announced in Milan

Date:9/8/2009

nces ) read the motivation for the assignment of the Science of New Materials Award to Michael Grtzel for "his numerous contributions to the Science of New Materials and in particular for having invented and developed a new class of solar cells, devices that are intended to transform the sun's energy into electricity. In a Grtzel cell, quanta of light from the sun are captured by dye molecules, which release electrons to a network of semiconductor oxide nanoparticles, generating energy for electricity. The dye sensitized cell thus mimics the natural process used by green plants in photosynthesis, Grtzel's discoveries also have important practical applications in the production of sustainable energy.

The President of the General Prize Committee, Professor Salvatore Veca, announced that the 2010 Balzan Prizes will be awarded in the following fields: History of Europe 1400-1700; History of the Theater; Biology of Stem Cells and their Potential Applications; Mathematics (Pure or Applied). The award fields vary each year and can be related to either a specific or an interdisciplinary field, and look to go beyond the traditional subjects both in the humanities (literature, the moral sciences and the arts) and in the sciences (medicine and the physical, mathematical and natural sciences), so as to give priority to innovative research.

Half of the one million Swiss Francs received by the winner of each of the four subjects must be destined for research work, preferably involving young scholars and researchers.

The press conference was held in the presence of the President of the Corriere della Sera Foundation Piergaetano Marchetti and the City Official for Culture Massimiliano Finazzer Flory, and was followed by a lecture by Luigi Luca Cavalli-Sforza, 1999 Balzan Prize for the Science of Human Origins, entitled "Italian Culture: a multidisciplinary history".

'/>"/>

Contact: Susannah Gold
susannah@goldcommunications.net
917-207-5375
Gold Communications
Source:Eurekalert

1

GOOD

Page: 1 2
Related medicine news :

1. Balzan Foundation announced 2008 prize winners
2. BIG research offers insight into aging -- 2 scientists awarded $200,000 prize
3. Dr. James OConnell Named J.H. Kanter Prize Laureate
4. Detroit Physician Herbert C. Smitherman, Jr., M.D., Awarded $25,000 in J.H. Kanter Prize Competition
5. Detroit Physician Among 10 Finalists for J.H. Kanter Prize
6. CandleInTheWindow.org Announces $1000 Scholarship Prize Winners
7. Miller-McCune Magazine Wins Environmental Journalism Prize
8. Jackson, Rockefeller obesity researchers share Shaw Prize
9. Prize4Life and the Alzheimer Research Forum Announce Launch of New Web-Portal for ALS Research
10. March of Dimes Awards $250,000 Prize to Scientists Unraveling the Causes of Muscular Dystrophy
11. 2009 Pizzigati Prize for Public Interest Computing Awarded to Darius Jazayeri

Post Your Comments:

(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...

(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...

(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...

(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...

(Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...

Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2 Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2 Health News:Research at the cutting edge of knowledge 2 Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2 Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3

[0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis [0] Research at the cutting edge of knowledge [0] Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts

... rates of hospital use, but they may be experiencing ... said in the latest edition of the Medical ... Melbourne-based Refugee Health Research Centre, Dr Ignacio Correa-Velez, and ... financial years to June 2004. ,'We found ...

... -- The science has long been clear that smoking causes ... damage from a father who smokes . ,Canadian ... in the DNA sequence of sperm cells, alterations that could ... are published in the June 1 issue of Cancer Research, ...

... market is estimated at around $2.5 trillion per annum, ... percent per annum. A radical shift in food consumption ... ,In markets, especially in the developed world, with ... is rapidly increasing. Besides, the emerging health-conscious newer generation ...

... released by a growing tumor could one day become ... chemotherapy and radiation treatment in people with advanced throat ... 1, 2007, issue of Clinical Cancer Research. ... Communication Disorders (NIDCD) and National Cancer Institute (NCI), two ...

... Researchers have found that patients with obstructive sleep apnea ... dead cells (apoptotic cells) from the lining (endothelium) of ... who do not have OSA. The finding may help ... for cardiovascular disease (CVD). ,According to the ...

... In a retrospective study of 700 patients with ... be significantly higher in HIV-infected patients compared ... TB relapse rates were higher in HIV-infected patients ... compared to those receiving daily or longer treatment. ...

Cached Medicine News:Health News:Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring 2 Health News:Nutrient-rich Dairy Beverages an Emerging Market 2 Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 2 Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 3 Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 4 Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2 Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3 Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2

Refugees No Burden On Health System Cigarette Smoke Alters DNA in Sperm, Genetic Damage Could Pass to Offspring Nutrient-rich Dairy Beverages an Emerging Market Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients Patients With OSA at Higher Risk for Cardiovascular Disease Treatment Outcomes of Patients With HIV and Tuberculosis

(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...

(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...

(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue: ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ... Summary ...

Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4

[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...

... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009. Gross profit was ...

Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6 Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7 Transgenomic Reports Fourth Quarter Financial Results 2 Transgenomic Reports Fourth Quarter Financial Results 3 Transgenomic Reports Fourth Quarter Financial Results 4 Transgenomic Reports Fourth Quarter Financial Results 5 Transgenomic Reports Fourth Quarter Financial Results 6 Transgenomic Reports Fourth Quarter Financial Results 7

Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer Transgenomic Reports Fourth Quarter Financial Results

Inquire...

Remote Blower With Bag-In/Bag-Out Option...

Class II Type B2 Biological Safety Cabinet...

Class II Type A2 Biological Safety Cabinet...

Medicine Products:

Benchtop Laminar Hood (Universal Hood)Remote Blower With Bag-In/Bag-Out Option Class II Type B2 Biological Safety Cabinet Class II Type A2 Biological Safety Cabinet